NewCardio Stock

NewCardio Liabilities

The The Liabilities of NewCardio (NWCI) as of Aug 12, 2026 is 6.01 M USD.

Liabilities

6.01 MUSD

Last updated:

In 2026, NewCardio's total liabilities amounted to 6.01 M USD, a % difference from the - USD total liabilities in the previous year.

Access this data via the Eulerpool API

NewCardio Stock analysis

What does NewCardio do? NewCardio Inc is a leading company in the medical technology industry that specializes in the development and marketing of innovative solutions to improve cardiovascular diagnostics and patient monitoring systems. The company's history began in 2003 when a group of experts and experienced scientists from the medical technology industry decided to develop a new technology together to monitor the electrical activity of the heart. This technology was intended to allow for more accurate diagnosis of cardiovascular diseases and thus provide better treatment options. Over the following years, several patents were filed and the technology was further developed. In 2008, NewCardio Inc was finally founded with the goal of launching the portfolio. NewCardio Inc's business model is based on the development and marketing of CardioBip systems, the company's core technology. The CardioBip system is a non-invasive, wireless, ECG-supported monitoring platform to improve cardiovascular diagnostics. The system is based on the analysis of real-time ECG data transmitted via Bluetooth to a smartphone or other mobile device. The company operates several business areas, including medical technology, clinical trials, and KinetoGen. The medical technology division focuses on the development and marketing of products that improve cardiovascular diagnostics. The CardioBip system is the core product of the medical technology division, but other products such as CardioVolt, CardioCore, and CardioKit are also available. These products offer a variety of features that improve cardiovascular diagnostics and offer numerous applications. The clinical trials division provides support for conducting clinical trials. The company offers digital, wireless ECG monitoring and efficient data analysis to ensure better clinical research. NewCardio's products enable more efficient conduct of clinical trials, saving time and costs. The KinetoGen division is a joint venture with Kineticor, a company that develops technologies for monitoring patients after surgical procedures. The joint venture specializes in the development of products that improve the prognosis and management of postoperative cardiovascular disorders. NewCardio Inc is committed to providing innovative solutions and technologies to improve cardiovascular diagnostics. NewCardio's products are unique in the market as they represent a wireless, non-invasive solution for monitoring cardiovascular diseases. Overall, NewCardio Inc is a unique company whose products and technologies improve cardiovascular diagnostics and optimize patient care. The company is focused on growth and continues to work on developing new innovative solutions to expand its portfolio. NewCardio is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing NewCardio's Liabilities

NewCardio's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating NewCardio's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing NewCardio's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

NewCardio's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in NewCardio’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about NewCardio stock

The Liabilities of NewCardio is 6.01 M USD in 2026.

On Eulerpool you can find the complete historical development of The Liabilities NewCardio since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's NewCardio historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — NewCardio

All Key Metrics — NewCardio